ASH 2018 | High treatment attrition in newly diagnosed multiple myeloma patients
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses a study investigating the number of newly diagnosed, non-transplanted multiple myeloma patients who are receiving a line of therapy that can progress to a subsequent line of therapy. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Fonseca describes the high level of treatment attrition measured in the study, with a 50% drop in the number of patients able to progress in their therapy.
Get great new content delivered to your inboxSign up